Prediction of steady‐state imipramine and desmethylimipramine plasma concentrations from single‐dose data
- 1 May 1979
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 25 (5part1) , 605-610
- https://doi.org/10.1002/cpt1979255part1605
Abstract
Tricyclic antidepressant plasma levels were measured in patients and healthy subjects after a single dose of desmethylimipramine (DM1) or imipramine (IMl) and after chronic dosing to steady states. Tricyclic plasma levels measured 24 hr after the single oral dose correlated with steady-state plasma levels. In patients receiving DM1 there was a correlation (r = 0.97, n = 10) between 24-hr and steady-state DM1 levels, while in normal subjects receiving IMI the correlation was r = 0.92 (n = 20) between 24-hr and steady-state total tricyclic levels (IMI plus its metabolite, DMI). These results suggest the possibility that after a test dose of tricyclic antidepressant, a patient may be put on a “therapeutic” dosage regimen without delay.This publication has 5 references indexed in Scilit:
- Nortriptyline in depressed patients with high plasma levels. IIClinical Pharmacology & Therapeutics, 1978
- Radioimmunoassay of imipramine and desmethylimipramineLife Sciences, 1978
- Imipramine: Clinical effects and pharmacokinetic variabilityPsychopharmacology, 1977
- Steady-state kinetics of imipramine in patientsPsychopharmacology, 1977
- THERAPEUTIC IMPLICATIONS OF TRICYCLIC ANTIDEPRESSANT PLASMA LEVELSJournal of Nervous & Mental Disease, 1976